The FDA has launched a 'safer technologies program' (STEP) aimed at medical devices and device-led combination products that enhance safety without qualifying for the breakthrough devices program. This initiative allows for expedited assessments while maintaining regulatory submission requirements, targeting devices that significantly improve the benefit-risk profile for non-life-threatening conditions. Comments on the draft guidance released on September 19, 2019, will be accepted until November 11, 2019.